AB Science S.A., a pharmaceutical company, engages in the discovery, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicines. The company markets Masitinib for the treatment of oncology and inflammatory diseases for dogs and cats. It markets its Masitinib under the Masivet brand name in Europe; and Kinavet brand name in the United States. The company is also developing Masitinib in human indications that are in various Phase II and Phase III clinical trials for the treatment of oncology, inflammatory, hematology, and central nervous system diseases, as well as for the treatment of indolent systemic mastocytosis, non controlled severe asthma, refractory rheumatoid arthritis, progressive forms of multiple sclerosis, amyothrophic lateral sclerosis, and Alzheimer's diseases. It serves hospitals and specialist physicians. AB Science S.A. was founded in 2001 and is headquartered in Paris, France.
ab science sa (AB:Euronext Paris)
3, Avenue George V
Phone: 33 1 47 20 00 14
Fax: 33 1 47 20 24 11www.ab-science.com
|No competitor information is available for AB.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact AB SCIENCE SA, please visit www.ab-science.com. Company data is provided by Capital IQ. Please use this form to report any data issues.